2024-05-03 05:07:08 ET
Kymera Therapeutics, Inc. (KYMR)
Q1 2024 Earnings Conference Call
May 2, 2024 8:30 a.m. ET
Company Participants
Justine Koenigsberg - Vice President, Investor Relations
Nello Mainolfi - President and Chief Executive Officer
Jared Gollob - Chief Medical Officer
Bruce Jacobs - Chief Financial Officer
Conference Call Participants
Brad Canino - Stifel Nicolaus
Eric Joseph - J.P. Morgan
Andy Chen - Wolfe Research
Divya Rao - TD Cowen & Company
Nat Charoensook - Leerink Partners
Vikram Purohit - Morgan Stanley
Geoff Meacham - Bank of America
Kelly Shi - Jefferies
Jeff Jones - Oppenheimer
Presentation
Operator
Good day, and welcome to the Kymera Therapeutics First Quarter 2024 Results Conference Call. All participants will be in the listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note that this event is being recorded.
I would now like to turn the conference over to Justine Koenigsberg. Please go ahead.
Justine Koenigsberg
Thank you. Good morning, and welcome to Kymera's quarterly update call. Joining me this morning are Nello Mainolfi, President and CEO; Jared Gollob, our Chief Medical Officer; and Bruce Jacobs, our Chief Financial Officer. Following our prepared remarks, we will open the call to questions. To have enough time to address everyone's questions, we ask that you please limit your questions to one, and a relevant follow-up.
Before we begin, I would like to remind you that today's discussion will include forward-looking statements about our future expectations, plans, and prospects. These statements are subject to risks and uncertainties that may cause the actual results to differ materially from those projected. A description of these risks can be found in our most recent 10-Q filed with the SEC. Any forward-looking statements speak only as of today's date, and we assume no obligation to update any forward-looking statements made on today's call.
With that, I'll now turn the call over to Nello.
Nello Mainolfi
Thank you, Justine. Good morning, everybody. It's been a very productive beginning of 2024, starting in January with an extensive update at our Immunology R&D Day, and a subsequent financing to provide capital that we will invest in our expanding clinical development efforts and growing pipeline. Past quarters we focused on execution on both our preclinical and clinical pipeline, as well as external engagement across the variety of business and medical conferences. Today, our plan is to share a brief update on our programs, as well as timelines for new [indiscernible] we're expecting through the rest of this year, and early '25....
Read the full article on Seeking Alpha
For further details see:
Kymera Therapeutics, Inc. (KYMR) Q1 2024 Earnings Call Transcript